- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | NEONC TECHNOLOGIES HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| Mi | NeOnc Technologies Holdings, Inc.: NeOnc Receives FDA Written Feedback on NEO212 CMC Development and Capsule-to-Tablet Transition | 1 | GlobeNewswire (USA) | ||
| 02.07. | NEONC TECHNOLOGIES HOLDINGS, INC. - 8-K, Current Report | 18 | SEC Filings | ||
| 24.06. | 24/7 Market News and NeOnc Technology: NeOnc Ignites Explosive Summer: 4 New Research Reports + UAE/Dubai Drug Approval Fuel Breakout Momentum | 1 | GlobeNewswire (USA) | ||
| 23.06. | NEONC TECHNOLOGIES HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 23.06. | NeOnc receives UAE approval for NEO100 glioma drug trials | 1 | Investing.com | ||
| NEONC TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
| 23.06. | NeOnc Technologies Holdings, Inc.: NeOnc Technologies Receives UAE IND Approval for NEO100, Expanding Global Development Ahead of Anticipated Phase 2 Data Milestone | 203 | GlobeNewswire (Europe) | Authorization covers all three NEO100 programs across adult Phase 1 through Phase 2, plus pediatric studies Extends NeOnc's UAE footprint beyond NEO212 and complements ongoing U.S. development, where... ► Artikel lesen | |
| 22.06. | WallStreet-PR: WSTPR Catalyst Watch: Abu Dhabi Regulatory Clearance Adds Momentum to NeOnc's Global Neuro-Oncology Strategy | 342 | Newsfile | Houston, Texas--(Newsfile Corp. - June 22, 2026) - NeOnc Technologies Holdings (NASDAQ: NTHI) recently achieved what many biotechnology companies spend years attempting to secure: international... ► Artikel lesen | |
| 16.06. | 24/7 Market News and NeOnc Technology: Brain Cancer Innovator NeOnc Heads into Critical Data Season with Fresh Abu Dhabi IND | 1 | GlobeNewswire (USA) | ||
| 16.06. | NeOnc Technologies Holdings, Inc.: NeOnc Technologies Secures UAE IND Approval for NEO212 Following Successful Phase 1 Completion, Advancing Toward Global Phase 2 Development | 1 | GlobeNewswire (USA) | ||
| 15.06. | WallStreet-PR: WSTPR Catalyst Watch: NeOnc Strengthens Capital Position Ahead of Potentially Transformational Neuro-Oncology Updates | 279 | Newsfile | Houston, Texas--(Newsfile Corp. - June 15, 2026) - NeOnc Technologies Holdings (NASDAQ: NTHI) continues to attract attention within the biotechnology sector as the Company advances its neuro-oncology... ► Artikel lesen | |
| 12.06. | NeOnc Technologies secures $5M private placement via Series A preferred stock | 12 | Seeking Alpha | ||
| 12.06. | NEONC TECHNOLOGIES HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 29.05. | 24/7 Market News and NeOnc Technology: The Next Great AI Revolution May Be Drug Delivery | 3 | GlobeNewswire (USA) | ||
| 19.05. | 24/7 Market News and NeOnc Technology: NeOnc Technologies Gains Growing Institutional Support Ahead of Key Brain Cancer Clinical Milestones | 1 | GlobeNewswire (USA) | ||
| 18.05. | NEONC TECHNOLOGIES HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 18.05. | NeOnc Technologies Holdings GAAP EPS of -$0.38 | 3 | Seeking Alpha | ||
| 18.05. | NeOnc Technologies Holdings, Inc.: NeOnc Provides Business Update and Reports Q1 2026 Financial Results | 901 | GlobeNewswire (Europe) | CALABASAS, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) ("NeOnc" or the "Company"), a clinical-stage biopharmaceutical company advancing two Phase 2 programs... ► Artikel lesen | |
| 07.05. | 24/7 Market News and NeOnc Technology: Biotech's Next Wave May Already be in Motion | 1 | GlobeNewswire (USA) | ||
| 24.04. | NEONC TECHNOLOGIES HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings |
1 2 3 Weiter >>
57 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVAVAX | 7,130 | -0,97 % | Novavax, Inc.: Novavax Reports First Quarter 2026 Financial Results and Operational Highlights | Total revenue of $140 million in the first quarter of 2026
Pfizer agreement announced in January for non-exclusive license to utilize Matrix-M® in two infectious... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 9,000 | +6,19 % | Palatin Technologies, Inc.: Palatin to Begin Trading on Nasdaq Stock Exchange | PRINCETON, N.J., May 18, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company focused on the discovery and development... ► Artikel lesen | |
| OCUGEN | 1,186 | -1,33 % | Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa | Cumulative sales milestones up to $255 million and modest upfront/near-term development milestonesRoyalties equaling 22% of net salesOcugen to manufacture and supply OCU400 MALVERN, Pa., July 13,... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,294 | -9,54 % | NurExone-Tochter Exo-Top nimmt mexikanischen Exosomenmarkt ins Visier | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,253 | -4,17 % | PacBio to Report Second Quarter 2026 Financial Results on August 5, 2026 | ||
| REDHILL BIOPHARMA | 0,705 | -3,56 % | RedHill Biopharma Ltd.: RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation | The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to opaganib1 for the treatment of neuroblastoma, a type of cancer most... ► Artikel lesen | |
| ONCO-INNOVATIONS | 0,385 | -1,28 % | Onco-Innovations Limited: Onco-Innovations Completes Analytical Reference Standard Preparation Program for ONC010's API | VANCOUVER, BC / ACCESS Newswire / July 10, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") announces the successful completion of its... ► Artikel lesen | |
| NOVOCURE | 13,385 | -6,72 % | JPMorgan nimmt NovoCure-Bewertung mit "Neutral" wieder auf | ||
| REVOLUTION MEDICINES | 163,45 | +4,37 % | Revolution Medicines: Nach Bauchspeicheldrüsenkrebs-Durchbruch - geht jetzt alles ganz schnell? | Eine Revolution im wahrsten Sinne des Unternehmensnamens: Die Biotech-Gesellschaft Revolution Medicines kann einen Paradigmenwechsel zur Behandlung von Bauchspeicheldrüsenkrebs einleiten. Die Datenlage... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 8,050 | 0,00 % | Citizens reiterates Ocular Therapeutix stock rating on Dextenza sales | ||
| ROCKET PHARMACEUTICALS | 3,020 | +1,00 % | ROCKET PHARMACEUTICALS, INC. - S-8, Securities to be offered to employees in employee benefit plans | ||
| PALISADE BIO | 1,965 | +3,97 % | Palisade Bio, Inc.: Palisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative Colitis | ASCENTRA-UC expected to enroll up to 204 patients with moderately to severely active ulcerative colitis across North America and Europe First patient enrollment anticipated in the second half of 2026... ► Artikel lesen | |
| ONCOLYTICS BIOTECH | 0,850 | -3,75 % | Oncolytics Biotech, Inc.: Oncolytics Biotech Reports FDA Regulatory Milestone and Strong Clinical Progress in Randomized RAS-Mutant MSS Colorectal Cancer Trial | Half of planned clinical sites will be activated this month; more than 20 patients have been pre-identified across participating centers Company to hold Type D meeting with FDA to discuss a potential... ► Artikel lesen | |
| OUTLOOK THERAPEUTICS | 1,220 | -4,01 % | Outlook Therapeutics, Inc. - 8-K, Current Report | ||
| OMEROS | 8,260 | +2,48 % | Omeros (OMER) is Amongst The Best Names Under $10 That Could Yield More Than 200% Return |
NEONC TECHNOLOGIES HOLDINGS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +5,54 % bei einem Aktienkurs von 3,430 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NEONC TECHNOLOGIES HOLDINGS INC finden Sie auf Wallstreet Online.